NantHealth

NantHealth is a transformational healthcare company converging science and technology through an integrated clinical platform that’s empowering physicians, patients, payers, and researchers to transcend the traditional barriers of today’s healthcare system. The Company's solutions are advancing diagnostics to better identify and target specific disease characteristics; transforming clinical delivery with clinical data and promoting wellness for a healthier.
Company Growth (employees)
Type
Public
HQ
Culver City, US
Founded
2007
Size (employees)
922 (est)
NantHealth was founded in 2007 and is headquartered in Culver City, US

Key People/Management at NantHealth

Patrick Soon-Shiong

Patrick Soon-Shiong

CEO and Chairman of the Board
Paul A. Holt

Paul A. Holt

CFO
Ron Louks

Ron Louks

COO

NantHealth Office Locations

NantHealth has offices in Culver City and London
Culver City, US (HQ)
9920 Jefferson Blvd
London, GB
Warnford Court, 29 Throgmorten Street
Show all (2)

NantHealth Financials and Metrics

NantHealth Financials

NantHealth's revenue was reported to be $100.4 m in FY, 2016
USD

Revenue (Q3, 2017)

21.8 m

Gross profit (Q3, 2017)

10.3 m

Gross profit margin (Q3, 2017), %

47%

Net income (Q3, 2017)

(42.4 m)

EBIT (Q3, 2017)

(16 m)

Market capitalization (22-Dec-2017)

357.1 m

Cash (30-Sep-2017)

73.5 m
NantHealth's current market capitalization is $357.1 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

33.9 m58.3 m100.4 m

Revenue growth, %

72%72%

Cost of goods sold

24.2 m34.8 m72.3 m

Gross profit

9.7 m23.5 m28 m
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

19.5 m31.5 m25.4 m22.5 m26.2 m21.8 m

Cost of goods sold

13 m22.2 m17.2 m19 m16.7 m11.5 m

Gross profit

6.4 m9.3 m8.1 m3.5 m9.6 m10.3 m

Gross profit Margin, %

33%29%32%15%36%47%
USDFY, 2014FY, 2015FY, 2016

Cash

3.7 m6 m160.4 m

Accounts Receivable

2.4 m11.5 m13.7 m

Prepaid Expenses

1.6 m8.7 m5 m

Inventories

2.9 m2.1 m2.2 m
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

95.2 m75.8 m124.9 m92.7 m73.5 m

Accounts Receivable

17.2 m12.9 m8.9 m11.3 m12 m

Prepaid Expenses

8.7 m5.8 m5.8 m5.2 m4.2 m

Inventories

2.3 m1.8 m2.2 m2.2 m974 k
    USDFY, 2014FY, 2015FY, 2016

    Net Income

    (84.6 m)(72 m)(184.1 m)

    Depreciation and Amortization

    16.2 m(15.8 m)(30.9 m)

    Accounts Receivable

    468 k3.6 m8.1 m

    Inventories

    (2.3 m)982 k(570 k)
    USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Net Income

    (33.1 m)87.3 m(124.2 m)(41.1 m)(111.2 m)(153.6 m)

    Depreciation and Amortization

    7.8 m15.5 m23 m8.3 m16.4 m23.3 m

    Accounts Receivable

    4.8 m3.8 m9 m4.6 m2.2 m(500 k)

    Inventories

    (51 k)(196 k)(135 k)42 k6 k61 k
      Y, 2017

      Financial Leverage

      2.2 x
      Show all financial metrics

      NantHealth Operating Metrics

      NantHealth's Active Users was reported to be 450 k in May, 2017
      Q2, 2016Q3, 2016FY, 2016Q1, 2017May, 2017Q2, 2017Q3, 2017

      Covered Lives

      100 m100 m

      Customer Transactions

      30 m

      Patents (US)

      566663

      Patents (foreign)

      11111
      Show all operating metrics

      NantHealth Acquisitions / Subsidiaries

      Acquired CompanyDateDeal Size
      NantHealth Singapore Pte Ltd
      Net. Orange, Ltd
      NaviNet, Inc.
      NaviNet Limited
      AZ Home Health, LLC
      NantHealth Ltd
      Nant Health Canada, Inc.
      Assisteo Holding, Inc.
      NantHealth Technologies India Private Ltd

      NantHealth Market Value History

      NantHealth Revenue Breakdown

      NantHealth Expenses Breakdown

      NantHealth's Web-traffic and Trends

      NantHealth Online and Social Media Presence

      NantHealth News and Updates

      Cher sues NantHealth's Soon-Shiong again, asks for jury trial

      The iconic entertainer claims the biotech mogul lied to the LA Times about knowing she was a stakeholder in Altor Biosciences.

      Cher sues NantHealth's Patrick Soon-Shiong alleging stock sale fraud

      The legendary singer claims Soon-Shiong and other Altor board members hid the success of a promising cancer and AIDS/HIV drug.

      Altor investors amend suit against Patrick Soon-Shiong, claim mogul paid off board members

      Altor Bioscience stakeholders say the NantHealth CEO low-balled the company’s value and paid off two directors in an attempt to buy the company through a sweetheart deal.

      Patrick Soon-Shiong sued over capital investment in biotech firm

      A Precision Biologics stockholder is accusing the NantHealth founder and controlling board members of breaching contract and fiduciary duty.

      Patrick Soon-Shiong acquires stake in 6 California hospitals

      The move could help the NantHealth founder and billionaire biotech mogul, who is embroiled in various controversies, with precision medicine efforts.

      NantHealth founder Soon-Shiong hit with lawsuit over attempted takeover

      The lawsuit filed by D.C. attorneys Boyden Gray and Adam Walden alleges the biotech mogul is seeking to acquire Altor Bioscience through a sweetheart deal.
      Show more

      NantHealth Company Life and Culture

      You may also be interested in